DelveInsight’s, “Vasculitis Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Vasculitis pipeline landscape. It covers the Vasculitis pipeline drug profiles, including Vasculitis clinical trials and nonclinical stage products. It also covers the Vasculitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Vasculitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Vasculitis NDA approvals (if any), and product development activities comprising the technology, Vasculitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Vasculitis Pipeline Report

 

• DelveInsight’s Vasculitis pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Vasculitis treatment.

 

• The leading Vasculitis Companies includes CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics,  Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and many others.

 

• Promising Vasculitis Pipeline Therapies includes AMB 301, Research, program: kidney disorder therapeutics, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, CCX-168, Belimumab, and others.

 

• The Vasculitis companies and academics are working to assess challenges and seek opportunities that could influence Vasculitis R&D. The Vasculitis pipeline therapies under development are focused on novel approaches to treat/improve Vasculitis.

 

To explore more information on the latest breakthroughs in the Vasculitis Pipeline treatment landscape of the report, click here @ Vasculitis Pipeline Outlook

 

Vasculitis Overview

Vasculitis involves inflammation of the blood vessels. The inflammation can cause the walls of the blood vessels to thicken, which reduces the width of the passageway through the vessel. If blood flow is restricted, it can result in organ and tissue damage. Vasculitis can affect people at any age. Some forms affect blood vessels that go to or supply specific organs like your skin, eyes, or brain. Vasculitis can have general symptoms like fever, loss of appetite, weight loss, and fatigue. Treatment depends on what’s causing your vasculitis and which organs are affected. Corticosteroid medications, also known as steroids, are generaaly preferred to fight inflammation.

 

Latest Developmental Activities in the Vasculitis Treatment Landscape

• In October 2021, Novartis Pharmaceuticals initiated a randomized, parallel-group, double-blind, placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of Secukinumab 300 mg administered subcutaneously versus placebo, in combination with glucocorticoid taper regimen, in patients With Giant Cell Arteritis (GCA)
• Chemocentryx has launched TAVNEOS in the fourth quarter of 2021 following FDA approval on October 8, 2021, as an adjunctive treatment in adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis, in combination with standard therapy including glucocorticoids.
• ChemoCentryx received approval from European Union (EU) for its drug, Tavneos (avacopan), to treat adult patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis) in January 2022.
• In November 2021, InflaRx reported positive data from the European Phase II IXCHANGE study of vilobelimab, a first-in-class anti-C5a antibody, in patients with ANCA-associated vasculitis (AAV). The study achieved its principal objective, demonstrating comparable clinical response of vilobelimab to the standard of care, while significantly reducing the need for glucocorticoid (GC) treatment.
• In November 2021, U.S. FDA’s Office For Orphan Products Development (OOPD) granted the orphan drug status for Ambulero’s gene therapy candidate, AMB-301, to treat Buerger’s Disease (BD), also known as Thromboangiitis Obliterans (TAO).
• Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated in Phase III clinical trial to treat Giant Cell Arteritis.
• Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate in the Phase II stage of development.

 

For further information, refer to the detailed Vasculitis Unmet Needs, Vasculitis Market Drivers, and Vasculitis Market Barriers, click here for Vasculitis Ongoing Clinical Trial Analysis

 

Vasculitis Emerging Drugs Profile

 

Upadacitinib: AbbVie

Upadacitinib(RINVOQ) is discovered and developed by AbbVie scientists.RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs. JAK-2, JAK-3 and TYK-2. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.Phase III trials of RINVOQ in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.

 

Belimumab: GlaxoSmithKline

Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response. It is being studied in phase III stage of development for the treatment of Anti-neutrophil cytoplasmic antibody-associated Vasculitis. 

 

Secukinumab :Novartis

Secukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin 17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and Drug Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis. There also are experimental and preclinical data that point towards a role for IL-17A in the pathogenesis of giant cell arteritis, and therefore IL-17A inhibition by blocking vascular inflammation is potentially a new therapeutic target. Secukinumab showed promise as a steroid-sparing agent in giant cell arteritis. Currently the drug is in Phase III stage of evaluation for the treatment Giant Cell Arteritis (GCA). Giant cell arteritis (GCA) is the most common form of vasculitis that occurs in adults.

 

Vasculitis Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Vasculitis. The companies which have their Vasculitis drug candidates in the most advanced stage, i.e. phase III include AbbVie.

 

Request a sample and discover the recent advances in Vasculitis Ongoing Clinical Trial Analysis and Medications, click here @ Vasculitis Treatment Landscape

 

Scope of the Vasculitis Pipeline Report

 

• Coverage- Global

 

• Vasculitis Companies- CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics,  Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and many others.

 

• Vasculitis Pipeline Therapies- AMB 301, Research, program: kidney disorder therapeutics, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, CCX-168, Belimumab, and others.

 

• Vasculitis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

 

Dive deep into rich insights for drugs for Vasculitis Market Drivers and Vasculitis Market Barriers, click here @ Vasculitis Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Vasculitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Vasculitis – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Vasculitis Collaboration Deals
9. Late Stage Products (Phase III)
10. Upadacitinib: AbbVie
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. Drug Name: Company Name
14. Drug profiles in the detailed report…..
15. Preclinical Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Vasculitis Key Companies
20. Vasculitis Key Products
21. Vasculitis- Unmet Needs
22. Vasculitis- Market Drivers and Barriers
23. Vasculitis- Future Perspectives and Conclusion
24. Vasculitis Analyst Views
25. Vasculitis Key Companies
26. Appendix

 

Got Queries? Find out the related information on Vasculitis Mergers and acquisitions, Vasculitis Licensing Activities @ Vasculitis Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services